Summary The carcinogenic activity of the alkylating agent methyl methanesulphonate (MMS) was investigated in the F344 rat bladder, both untreated and pretreated with a single threshold dose of N-methyl-N-nitrosourea (MNU). On its own, 6 doses of 2.5mg MMS produced a 7% incidence of bladder cancer. After a single intravesical instillation of MNU, the same MMS treatment produced a bladder cancer incidence of 56%. This was significantly higher than the incidence (24%) observed after treatment with MNU alone, and greater than the sum of the lesions produced by either treatment alone. By reference to the mouse skin multistage carcinogenesis model, it is argued that MMS is a complete, albeit weak carcinogen with little initiating but powerful late-stage activity. Its promoting activity is most probably attributable to its potent mitogenic action and in this model it is analogous to a stage 2, rather than a stage 1 skin promoter.
The alkylating agent, methyl methanesulphonate (MMS) is cytotoxic and produces regenerative urothelial hyperplasia when instilled directly into the rat bladder (Wakefield & Hicks, 1974; Tudor et al., 1983) . Recently, we showed that over longer periods, multiple doses of MMS induce a milder but more persistent urothelial hyperplasia with little or no dysplasia (Tudor et al., 1983) . In addition, fotur well-differentiated lesions with abnormal growth patterns were observed (either papillary/nodular hyperplasia or papillary carcinoma), but their occurrence was not doserelated.
We suggested that these findings did not necessarily reflect an initiating potential of MMS, but rather indicated that MMS could act as a promoter or late-stage carcinogen either in previously initiated cells or in cells carrying a latent oncogene.
The present study was undertaken to investigate whether multiple doses of MMS can indeed promote tumour development in previously initiated rat bladder. A low dose of N-methyl-Nnitrosourea (MNU) was used as the initiating agent.
Materials and methods
rooms maintained at 19-22°C with a relative humidity of 50-60% and 12h of artificial light during the daytime. Basic diet was Dixon's 41B containing 1.03% calcium, 0.53% phosphorus and 0.21% magnesium (E. Dixon and Co., Ware, Hertfordshire) and drinking water was taken from the mains supply; both were available ad libitum. The animals were 6-8 weeks old at the beginning of treatment, and were killed after 2 years or earlier if they appeared moribund or developed symptoms such as haematuria or a palpable pelvic mass. Chemicals MNU was synthesized by Dr A.K. Wallis in the Courtauld Institute of Biochemistry, Middlesex Hospital Medical School, by the method of Werner (1919) . Its purity was checked by melting-point determination and high pressure liquid chromatography as detailed previously (Severs et al., 1982) . MMS was obtained from Cambrian Chemicals Ltd., Croydon, Surrey and used as supplied. Small, preweighed aliquots of both chemicals were stored in light-proof, screw-capped vials at -20°C. In thickened or tumour-bearing bladders, representative samples of each thickened area or tumour were prepared for both wax and resin embedding. Bladders from animals found dead were processed for wax histology only. Other organs were examined for gross abnormalities, and the kidneys and liver routinely processed for histology.
Results

Bladder pathology
The terminal bladder pathology is shown in Tables   Table I Terminal (18) 19(58)C aBladders were from rats surviving to 2 years after the initial dose plus those killed in extremis or found dead after detection of the first bladder tumour at 60 weeks.
bP/N refers to urothelial hyperplasias with a papillary/nodular growth pattern. I and II. The criteria used in the diagnosis of urothelial lesions are those currently in use in this laboratory and have been published previously Tudor et al., 1983 Group C. MMS alone In animals that received six doses of MMS, urothelial hyperplasias were also numerous, affecting 68% of the animals (Table I) . Although most were mild and focal, moderate simple hyperplasia was present in five animals. All hyperplasias were differentiated, but in the more severe lesions the superficial cells often appeared rounded and immature. Mild urothelial dysplasias were less severe than those produced by MNU alone and were notably less frequent.
Two transitional cell carcinomas were detected in animals from this group (Table II) . One was a large exophytic papillary tumour very comparable to that illustrated previously in an MMS-treated animal (Tudor et al., 1983) . It had early invasion of the underlying lamina propria (Plb) and a small area of squamous metaplasia. A large, single free-lying calculus was present within this bladder. The other neoplasm had a different growth pattern with an inverted papillary structure invading the underlying lamina propria (Figures 4a, 4b) (Figure 5 ). In addition, occasional more severe dysplasia was observed, characterized by considerable variation in size, shape and staining density of nuclei, loss of normal cell and nuclear polarity and the presence of highly irregular nuclear profiles (Figure 6 ).
Transitional cell carcinoma was the most frequent urothelial lesion observed in this group, accounting for 58% of the bladders examined ( Figure 7 , Table II ). Papillary transitional cell carcinomas were recorded in 17 bladders with invasion of the lamina propria (Plb) in seven ( Figure 8) . Generally, the histopathology of these lesions was more severe than that produced by MNU or MMS alone (Figures 9-11 ). Multifocal papillary neoplasias were observed in three bladders and squamous metaplasia in four. Two other bladders had foci of carcinoma in situ within areas of either papillary or nodular urothelial hyperplasia (Figure 12 ).
Pathology of other organs
Neoplastic and non-neoplastic lesions observed in organs other than the bladder were similar to those reported previously in F344 rats (Sass et al., 1975;  Coleman et al., 1977; Goodman et al., 1979) . None of these lesions was treatment-related.
All animals had some degree of renal pathology. Ninety-eight percent of kidneys were affected by the degenerative lesion "chronic nephropathy" (Coleman et al., 1977) . Frequently chronic interstitial nephritis was present in these affected kidneys. Other occasional changes included small foci of cortico-medullary mineralization and hyperplasia of the pelvic transitional epithelium. In one animal from group D (MNU + 6 x MMS) an irregularly shaped calculus was associated with a transitional cell carcinoma of the pelvic epithelium and ureter proximal to the kidney. The bladder from the same animal contained multifocal transitional cell carcinomas.
Much of the hepatic material examined was normal, although bile-duct hyperplasia usually with concurrent sclerosis, was observed in 38% of animals. Other occasional focal hepatic lesions included necrosis, fatty change and chronic hepatitis. No hyperplastic nodules or hepatic neoplasms were detected.
Gross lesions observed in other tissues taken at post-mortem and subsequently examined histologically, were similar to those previously reported and appear to be characteristic for the F344 rat D (Goodman et al., 1979 (Slaga, 1983 (Weinstein, 1983) . This permits expression of the tumour phenotype thus conferring an altered proliferative capacity upon these premalignant cells. (Moolgavkar & Knudson, 1981) .
The biological and pathological events associated with promotion in skin and other tissues have been reviewed recently (Hicks, 1983a) . In experimental bladder cancer models, sodium cyclamate, sodium saccharin, phenacetin and tryptophan all significantly increase the incidence of bladder cancer in rats previously treated with threshold doses of bladder carcinogens (Hicks, 1983b) . Such compounds act as late-stage carcinogens and accelerate the development of transitional cell carcinoma in carcinogen-treated urothelia. Because they have the ability to increase tumour yield above that produced by a low dose of carcinogen alone, they have been regarded as promoters, but the data supporting the possibility that they have stage 1 promoting activity is not conclusive (Hicks, 1983b) . With one exception (Hicks et al., 1975) , the carcinogen in these studies was not used at a subthreshold or initiating dose, but at a level sufficient to produce a few neoplasms on its own. Furthermore, there is no biochemical evidence that these agents activate protein kinase C to catalyse stage 1 promoting events in the bladder analogous to those produced, for example, by TPA in the skin. The published evidence is more consistent with these compounds acting as Stage 2 promoters, by supplying the proliferative stimulus necessary for clonal expansion. The role of MMS in bladder carcinogenesis reported here is evaluated in the light of these considerations.
The results (Tables I and II) demonstrate that MMS significantly increases the incidence of urothelial neoplasms in MNU-pretreated bladders by comparison with the number produced by MNU only. Furthermore, this increase far exceeds the sum of the numbers produced by either MNU or MMS alone. In addition, subsequent treatment with MMS reduced the time to detection of the first MNU-induced bladder tumour by 15 weeks, and the mean latent period by 10 weeks (Table II) . The increased tumour incidence, reduced induction time and potent hyperplastic activity of MSS (Tudor et al., 1983) are all characteristic of the action of skin promoters (Boutwell et al., 1982) and in an operational sense, MMS clearly acts as a promoter of carcinogenesis in the rat urinary bladder. In the present experiment, however, as in many other bladder promotion studies (see Hicks, 1983b) (Severs et al., 1982 (Bralow et al., 1973; Martin et al., 1974) .
The production of a few tumours by MMS alone shows it to be a complete, albeit weak, carcinogen. In the mouse skin model also, long-term applications of promoting agents including TPA produced a few skin tumours (Roe, 1956; Boutwell et al., 1957) , and it is doubtful whether such a thing as a "pure promoter" exists. Since MMS is capable of binding covalently to DNA, it is to be expected that it will have some initiating capacity. However, unlike the potent complete bladder carcinogen MNU, MMS is a comparitively weak alkylating agent which causes predominantly N-methylation with little 0-methylation of DNA residues (Lawley, 1976 (Lawley, , 1980 . It has been suggested that N-alkylation is associated with cytotoxicity whereas 0-alkylation is pro-mutagenic and hence initiating (Roberts et al., 1974; Peterson et al., 1979) and thus it could be predicted that MMS would have only weak initiating activity. In any case, the possession of initiating activity by a compound does not preclude it from acting primarily as a promoter in a defined situation, as demonstrated previously by Scribner & Scribner (1980) , with 7-bromo-methylbenz(a) anthracene in the mouse skin model.
Theoretically MSS may also influence the conversion of a benign tumour into an invasive carcinoma, i.e. act at the final stage in a multistage carcinogenesis system for MMS, like phorbol esters (Kinsella & Radman, 1978; Fusenig & Dzarlieva, 1982) , can bring about translocation of genetic material by inducing chromosomal abberrations and sister chromatid exchange (Perry & Evans, 1975) . The presence of several carcinomas showing an early invasive growth pattern in this multistage model system is evidence that this may well be the case.
Our results thus demonstrate that MMS is a weak complete bladder carcinogen but in an operational sense is a powerful promoting agent. This implies that it has weak initiating activity, but powerful late-stage carcinogenic potential. These experiments do not provide any evidence about the potency of MMS as a Stage 1 promoter in the bladder, but they do show it to have late-stage activity which may be attributable to its potent mitogenic action on the urothelium. Its action in the rat bladder is thus similar to that of 2-acetylaminofluorene (2-AAF) on the mouse bladder (Littlefield et al., 1979 ) and it appears to act predominantly as a Stage 2 promoter in this experimental multistage bladder cancer model.
